Literature DB >> 17620686

IVUS-guided evaluation and percutaneous intervention in an anomalous left main coronary artery.

Ryan G Schrale1, Keith M Channon, Oliver J Ormerod.   

Abstract

We report the case of a 42-year-old female with proven anterior ischemia and an anomalous origin of the left main coronary artery (ALMCA) who underwent successful percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) guidance. Angiographic and IVUS images demonstrate features unique to the ALMCA. The epidemiology, pathophysiology, evaluation and management options, including technical considerations for percutaneous intervention, are discussed. The ALMCA from the right sinus of Valsalva represents one of the few potentially serious congenital coronary artery anomalies. These patients are often young, have atypical presentation and carry a risk of sudden death. In combination with unfamiliar anatomy and pathophysiology, they pose serious diagnostic and therapeutic challenges. We present our experience in a patient who underwent successful PCI with IVUS guidance, and discuss the anatomy, pathophysiology, evaluation and treatment options for the ALMCA.

Entities:  

Mesh:

Year:  2007        PMID: 17620686

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  3 in total

Review 1.  Anomalous origination of a coronary artery from the opposite sinus.

Authors:  Joanna C E Lim; Andy Beale; Steve Ramcharitar
Journal:  Nat Rev Cardiol       Date:  2011-10-11       Impact factor: 32.419

2.  Percutaneous revascularization in a patient with anomalous origin of left main coronary artery.

Authors:  Rajesh Vijayvergiya; Anil Grover; Manphool Singhal
Journal:  World J Cardiol       Date:  2011-09-26

3.  Anomalous Aortic Origin of Coronary Arteries from the Opposite Sinus: A Case Report.

Authors:  Nitin Sabharwal; Abhinav Saxena; Aleksandre Toreli; Vineet Meghrajani; Bilal Malik; Jacob Shani
Journal:  Cureus       Date:  2018-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.